The Peptide Authority

Research Hub

Semaglutide Research and Human Clinical Trial Evidence

Semaglutide is a glucagon-like peptide-1 receptor agonist studied across obesity, weight management, type 2 diabetes, cardiovascular outcomes, appetite regulation, oral formulations, safety, and long-term treatment. Semaglutide is also the active compound used in branded medications including Wegovy, Ozempic, and Rybelsus; approved indications, formulations, and studied doses differ. This research hub organizes human clinical trials, systematic reviews, meta-analyses, and other verified research indexed in The Peptide Authority library. Every record links to its original PubMed or DOI source for independent verification.

Semaglutide is a prescription medication used for specific approved indications under the supervision of a licensed healthcare professional. This page summarizes published research and does not provide medical advice, prescribing guidance, dosing instructions, or individualized treatment recommendations.

Evidence Snapshot

24Publicly indexed Semaglutide records
2016–2025Current indexed publication range
6Featured research records
24 PubMed · 24 DOIVerified source links

Counts reflect the research records currently indexed in this hub and update as the library is expanded.

Evidence Summary

What Have Human Studies Shown?

Human studies have evaluated semaglutide across obesity and weight management, type 2 diabetes, cardiovascular outcomes, continued treatment and weight maintenance, oral formulations, and safety. The evidence represented in this library includes randomized clinical trials, systematic reviews, meta-analyses, and other verified human research linked directly to its PubMed or DOI source. Across these records, the strongest body of evidence concerns weight-related and glycaemic outcomes, while the available research also includes cardiovascular, formulation, maintenance, and safety questions.

The evidence should be interpreted within the populations, treatment durations, formulations, comparators, and endpoints used in each study. Some research areas on this page are represented by only one or a small number of records. The current collection does not establish identical outcomes for every patient, universal superiority over other treatments, long-term outcomes after discontinuation, or individualized treatment recommendations.

Research Areas

Obesity and weight-management researchType 2 diabetes and glycaemic outcomesCardiovascular outcomesContinued treatment and weight maintenanceOral Semaglutide researchSafety, tolerability, and systematic reviews

Weight Management

Obesity and Weight-Management Research

Human studies examining Semaglutide for obesity, body-weight reduction, appetite, weight-related outcomes, and comparisons with other incretin-based medications.

Diabetes Research

Type 2 Diabetes and Glycaemic Outcomes

Clinical research evaluating Semaglutide for glycaemic control, body weight, and treatment outcomes in adults with type 2 diabetes.

Cardiovascular Research

Cardiovascular Outcomes

Human research examining cardiovascular and heart-failure outcomes associated with Semaglutide and related incretin-based therapies.

Long-Term Outcomes

Continued Treatment and Weight Maintenance

Research examining longer-term weight outcomes, sustained treatment effects, and maintenance of weight reduction with Semaglutide.

Formulation Research

Oral Semaglutide Research

Research examining the pharmacokinetics, absorption, exposure, and clinical development of oral and injectable Semaglutide formulations.

Safety and Reviews

Safety, Tolerability, and Systematic Reviews

Safety research, systematic reviews, meta-analyses, observational findings, and ongoing clinical-development studies involving Semaglutide.

Research Context

What Are the Main Limitations of the Evidence?

Semaglutide findings vary by study population, formulation, comparator, treatment duration, and clinical endpoint. Several research areas in this library are supported by fewer records than the weight-management evidence, and the collection does not provide universal head-to-head comparisons or establish outcomes after treatment discontinuation. Readers should review each study's design, population, findings, and limitations through the linked original source. This page summarizes published research and does not provide medical advice, prescribing guidance, or individualized treatment recommendations.

Source and Editorial Standards

Study titles, authors, journals, publication years, PMIDs, DOIs, institutional affiliations, and source links are drawn from the existing indexed records. The Peptide Authority did not conduct or publish these studies. Inclusion does not imply endorsement by the original authors, institutions, journals, PubMed, manufacturers, or publishers.

Evidence Briefing

The Peptide Evidence Brief

Twice each month, receive the most important newly indexed studies, clinical trial updates, evidence summaries, and research developments, selected exclusively from trusted peer-reviewed journals.

Concise summaries with direct links to original publications. Quality over quantity. No promotional content.

Peer-reviewed sources onlyPublished twice monthlyNo promotional content

No spam. Unsubscribe at any time. We never share your data.